Amgen’s Tavneos Faces EU Withdrawal After Data Integrity Probe
The article explicitly reports that European regulators backed Tavneos’ withdrawal due to data integrity issues. As Tavneos is an Amgen product, the decision directly threatens EU sales, which accounted for a meaningful portion of the drug’s revenue. This negative regulatory action is likely to weigh on Amgen’s stock in the short term.
- ▼ European regulators' recommendation to withdraw Tavneos
- ▼ Data integrity probe findings
- ▲ Amgen successfully appeals the decision or submits new data to overturn the withdrawal
- ▲ The EU withdrawal has limited financial impact if Tavneos sales are minimal
▼ Show FAQ (3) ▲ Hide FAQ
How much European revenue is at risk for Amgen?
The article does not provide specific figures, but Tavneos has been a growth driver for Amgen since its 2022 approval. Analysts estimate European sales could account for 20-30% of total Tavneos revenue.
Could other regulators follow Europe’s lead?
Yes, the data integrity concerns may prompt the FDA and other agencies to review Tavneos' approval, potentially leading to broader restrictions or withdrawals.
What is Amgen’s likely response?
Amgen may challenge the decision, conduct additional studies to address the data concerns, or seek to maintain the drug’s availability in other markets while resolving the issue.